CagriSema vs. Semaglutide: Large Phase 3 Trial for Obesity and Type 2 Diabetes

Globally, obesity and type 2 diabetes (T2D) represent significant public health challenges, often co-occurring and leading to severe complications. While existing treatments like Semaglutide have shown considerable success in weight management and glycemic control, there's a continuous need for even more effective and safe therapeutic options. This upcoming Phase 3 clinical trial aims to directly compare the efficacy and safety of two different doses of CagriSema against Semaglutide alone in a large population of individuals living with these conditions.

This study is specifically designed to investigate the comparative efficacy and safety of CagriSema (a co-formulation combining cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist) versus Semaglutide (a GLP-1 receptor agonist) for body weight loss. The primary outcome measures will focus on the percentage change in body weight from baseline over the 72-week treatment period, alongside a comprehensive assessment of adverse events across all treatment groups. The central aim of this Phase 3 trial is to determine if CagriSema offers superior weight reduction and a favorable safety profile compared to Semaglutide in 2500 participants with obesity and/or type 2 diabetes. Researchers will quantitatively compare the mean body weight reduction achieved by each of the two CagriSema dose levels against the Semaglutide arm, looking for statistically significant differences (e.g., p<0.05). Secondary endpoints will likely include improvements in glycemic control, cardiovascular risk factors, and quality of life, although specific details are not yet publicly available.